The Motherisk Program, Division of Clinical Pharmacology, The Hospital for Sick Children, 555 University Avenue, Toronto, ON, M5G1X8, Canada.
Expert Rev Vaccines. 2013 Nov;12(11):1243-8. doi: 10.1586/14760584.2013.844651. Epub 2013 Oct 4.
Varicella infection during pregnancy is associated with serious maternal and fetal complications such as congenital varicella syndrome, maternal pneumonia and neonatal varicella. Pregnant women are ineligible to receive the varicella vaccination, thus women who lack evidence of immunity to varicella are at an increased risk for developing a varicella infection if exposed to a contagious individual. Presently, post-exposure prophylaxis involves the administration of a varicella zoster immunoglobulin (VariZIG™) to prevent or reduce the severity of an infection. The US FDA recently approved VariZIG for licensure and recommend that it be administered as soon as possible following VZV exposure, ideally within 96 h for greatest effectiveness. The following review critically examines the role of VariZIG in post-exposure prophylaxis of varicella during pregnancy.
孕期水痘感染可导致严重的母婴并发症，如先天性水痘综合征、母体肺炎和新生儿水痘。孕妇不能接种水痘疫苗，因此如果接触到传染性个体，没有水痘免疫力证据的孕妇发生水痘感染的风险会增加。目前，接触后预防包括使用水痘带状疱疹免疫球蛋白（Varicella zoster immunoglobulin，VariZIG）来预防或减轻感染的严重程度。美国食品药品监督管理局（FDA）最近批准 VariZIG 用于许可，并建议在 VZV 暴露后尽快（理想情况下在 96 小时内）使用，以获得最大效果。以下综述批判性地评估了 VariZIG 在孕妇水痘接触后预防中的作用。
